Avalyn Pharma

Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPO April 30, 2026 News Pulmonary fibrosis biotech Avalyn Pharma prices upsized IPO at $18, the high end of the range Avalyn Pharma, a Phase 2 biotech developing inhaled medicines... Read more